Open AccessIntraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites
Author(s) -
Zhouwei Zhan,
Xiaojie Wang,
Jiang Yu,
Jinwen Zheng,
Yi Zeng,
Mingyao Sun,
Peng Li,
Zengqing Guo,
Bi-juan Chen
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0896
Subject(s) - medicine , ascites , cisplatin , adverse effect , cancer , gastroenterology , endostatin , recombinant dna , oncology , chemotherapy , angiogenesis , biochemistry , chemistry , gene
Objective: To investigate the efficacy and safety of intraperitoneal administration of recombinant human endostatin in gastric cancer with malignant ascites. Methods: Clinical data of 90 patients (37 in an Endostar ® combined with cisplatin group and 53 in a cisplatin group) were retrospectively analyzed. The primary end point was overall survival, and the secondary end points were objective response rate (ORR), disease control rate (DCR) and so on. Results: Median overall survival was longer in the combination group (9.7 vs 8.1 months; p = 0.01). ORR and DCR were higher in the combination group (ORR: 75.7% vs 54.7%; p = 0.04; DCR: 94.6% vs 75.5%; p = 0.02). There were no significant differences in adverse effects between the two groups. Conclusion: Intraperitoneal administration of recombinant human endostatin improved efficacy and survival for gastric cancer with ascites.